{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:03:17Z","timestamp":1791356597580,"version":"4.3.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"vor","delay-in-days":365,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Metabolism"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.cmet.2014.05.001","type":"journal-article","created":{"date-parts":[[2014,6,5]],"date-time":"2014-06-05T16:18:05Z","timestamp":1401985085000},"page":"133-144","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":173,"title":["Liver Damage, Inflammation, and Enhanced Tumorigenesis after Persistent mTORC1 Inhibition"],"prefix":"10.1016","volume":"20","author":[{"given":"Atsushi","family":"Umemura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eek\u00a0Joong","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun\u00a0Hee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shabnam","family":"Shalapour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark\u00a0A.","family":"Valasek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam","family":"Aghajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekihiro","family":"Seki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael\u00a0N.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Karin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmet.2014.05.001_bib1","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1158\/1078-0432.CCR-06-2798","article-title":"The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy","volume":"13","author":"Abraham","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cmet.2014.05.001_bib2","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.2337\/db13-0106","article-title":"Evidence for rapamycin toxicity in pancreatic \u03b2-cells and a review of the underlying molecular mechanisms","volume":"62","author":"Barlow","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.cmet.2014.05.001_bib3","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nrd3531","article-title":"Rapamycin passes the torch: a new generation of mTOR inhibitors","volume":"10","author":"Benjamin","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.cmet.2014.05.001_bib4","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.cmet.2008.10.002","article-title":"Skeletal muscle-specific ablation of raptor, but not of rictor, causes metabolic changes and results in muscle dystrophy","volume":"8","author":"Bentzinger","year":"2008","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2014.05.001_bib5","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/hep.26323","article-title":"The mTOR pathway in hepatic malignancies","volume":"58","author":"Bhat","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.cmet.2014.05.001_bib6","doi-asserted-by":"crossref","first-page":"e53078","DOI":"10.1371\/journal.pone.0053078","article-title":"Profiling sirolimus-induced inflammatory syndrome: a prospective tricentric observational study","volume":"8","author":"Buron","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.cmet.2014.05.001_bib7","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJMoa021423","article-title":"Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults","volume":"348","author":"Calle","year":"2003","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cmet.2014.05.001_bib8","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.cmet.2013.03.015","article-title":"Sustained activation of mTORC1 in skeletal muscle inhibits constitutive and starvation-induced autophagy and causes a severe, late-onset myopathy","volume":"17","author":"Castets","year":"2013","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2014.05.001_bib9","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.molmed.2007.08.001","article-title":"Targeting the mTOR signaling network in cancer","volume":"13","author":"Chiang","year":"2007","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.cmet.2014.05.001_bib10","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.gde.2012.12.005","article-title":"mTOR in aging, metabolism, and cancer","volume":"23","author":"Cornu","year":"2013","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/j.cmet.2014.05.001_bib11","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.molcel.2010.06.022","article-title":"Activation of a\u00a0metabolic gene regulatory network downstream of mTOR complex 1","volume":"39","author":"D\u00fcvel","year":"2010","journal-title":"Mol. Cell"},{"key":"10.1016\/j.cmet.2014.05.001_bib12","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1172\/JCI44203","article-title":"S6 kinase 1 is required for\u00a0rapamycin-sensitive liver proliferation after mouse hepatectomy","volume":"121","author":"Espeillac","year":"2011","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.cmet.2014.05.001_bib13","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ctrv.2010.08.001","article-title":"Evolving strategies for the treatment of hepatocellular carcinoma: from clinical-guided to molecularly-tailored therapeutic options","volume":"37","author":"Faloppi","year":"2011","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.cmet.2014.05.001_bib14","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/978-1-61779-430-8_9","article-title":"Evaluation of rapamycin-induced cell death","volume":"821","author":"Galluzzi","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.cmet.2014.05.001_bib15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccr.2007.05.008","article-title":"Defining the role of mTOR in cancer","volume":"12","author":"Guertin","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cmet.2014.05.001_bib16","doi-asserted-by":"crossref","first-page":"e9197","DOI":"10.1371\/journal.pone.0009197","article-title":"Raptor is phosphorylated by\u00a0cdc2 during mitosis","volume":"5","author":"Gwinn","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.cmet.2014.05.001_bib17","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/nature08221","article-title":"Rapamycin fed late in life extends lifespan in genetically heterogeneous mice","volume":"460","author":"Harrison","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.cmet.2014.05.001_bib18","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ccr.2009.12.048","article-title":"Hepatocyte IKKbeta\/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation","volume":"17","author":"He","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cmet.2014.05.001_bib19","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.cell.2013.09.031","article-title":"Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling","volume":"155","author":"He","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.cmet.2014.05.001_bib20","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1126\/science.1715094","article-title":"Targets for cell cycle arrest by\u00a0the immunosuppressant rapamycin in yeast","volume":"253","author":"Heitman","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.cmet.2014.05.001_bib21","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1002\/cncr.11266","article-title":"Expression and prognostic role of tumor suppressor gene PTEN\/MMAC1\/TEP1 in hepatocellular carcinoma","volume":"97","author":"Hu","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.cmet.2014.05.001_bib22","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nature11861","article-title":"mTOR is a key modulator of ageing and age-related disease","volume":"493","author":"Johnson","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.cmet.2014.05.001_bib23","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1126\/science.1215135","article-title":"Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity","volume":"335","author":"Lamming","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.cmet.2014.05.001_bib24","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/S0076-6879(79)58168-3","article-title":"Liver cells","volume":"58","author":"Leffert","year":"1979","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.cmet.2014.05.001_bib25","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.drup.2007.11.003","article-title":"Targeting the PI3K\/Akt\/mTOR pathway: effective combinations and clinical considerations","volume":"11","author":"LoPiccolo","year":"2008","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.cmet.2014.05.001_bib26","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.cell.2005.04.014","article-title":"IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis","volume":"121","author":"Maeda","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.cmet.2014.05.001_bib27","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jhep.2011.06.012","article-title":"The use of sirolimus should be restricted in liver transplantation","volume":"56","author":"Massoud","year":"2012","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.cmet.2014.05.001_bib28","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.jhep.2013.11.031","article-title":"Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends","volume":"60","author":"Matter","year":"2014","journal-title":"J.\u00a0Hepatol."},{"issue":"Suppl 2","key":"10.1016\/j.cmet.2014.05.001_bib29","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1038\/onc.2009.352","article-title":"Common corruption of the mTOR signaling network in human tumors","volume":"27","author":"Menon","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.cmet.2014.05.001_bib30","doi-asserted-by":"crossref","first-page":"ra24","DOI":"10.1126\/scisignal.2002739","article-title":"Chronic activation of mTOR complex 1 is sufficient to cause hepatocellular carcinoma in\u00a0mice","volume":"5","author":"Menon","year":"2012","journal-title":"Sci. Signal."},{"key":"10.1016\/j.cmet.2014.05.001_bib31","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/imm.12126","article-title":"Rapamycin unbalances the polarization of human macrophages to M1","volume":"140","author":"Mercalli","year":"2013","journal-title":"Immunology"},{"key":"10.1016\/j.cmet.2014.05.001_bib32","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jhep.2013.08.025","article-title":"AMPK\u03b11 controls hepatocyte proliferation independently of energy balance by regulating Cyclin A2 expression","volume":"60","author":"Merlen","year":"2014","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.cmet.2014.05.001_bib33","doi-asserted-by":"crossref","first-page":"e2223","DOI":"10.1371\/journal.pone.0002223","article-title":"The yeast Tor signaling pathway is involved in G2\/M transition via polo-kinase","volume":"3","author":"Nakashima","year":"2008","journal-title":"PLoS ONE"},{"key":"10.1016\/j.cmet.2014.05.001_bib34","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1172\/JCI67674","article-title":"Rapamycin extends murine lifespan but has limited effects on aging","volume":"123","author":"Neff","year":"2013","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.cmet.2014.05.001_bib35","unstructured":"Novartis. (2013a). Novartis study of Afinitor\u00ae in advanced liver cancer does not meet primary endpoint of overall survival. [cited 2013 Aug 7]. Available from: http:\/\/www.novartis.com\/newsroom\/media-releases\/en\/2013\/1721562.shtml."},{"key":"10.1016\/j.cmet.2014.05.001_bib36","unstructured":"Novartis. Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma (EVOLVE-1). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2013b- [cited 2013 Aug 12]. Available from: http:\/\/clinicaltrials.gov\/show\/NCT01035229 NLM Identifier: NCT01035229."},{"key":"10.1016\/j.cmet.2014.05.001_bib37","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.cell.2009.12.052","article-title":"Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression","volume":"140","author":"Park","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.cmet.2014.05.001_bib38","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.trre.2013.06.001","article-title":"Review of combination therapy with mTOR inhibitors and tacrolimus minimization after transplantation","volume":"27","author":"Peddi","year":"2013","journal-title":"Transplant. Rev. (Orlando)"},{"key":"10.1016\/j.cmet.2014.05.001_bib39","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1128\/MCB.00322-09","article-title":"Mitotic raptor promotes mTORC1 activity, G(2)\/M cell cycle progression, and internal ribosome entry site-mediated mRNA translation","volume":"30","author":"Ram\u00edrez-Valle","year":"2010","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.cmet.2014.05.001_bib40","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nrc1974","article-title":"mTOR and cancer: insights into a complex relationship","volume":"6","author":"Sabatini","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cmet.2014.05.001_bib41","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/nature04869","article-title":"Ras, PI(3)K and mTOR signalling controls tumour cell growth","volume":"441","author":"Shaw","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.cmet.2014.05.001_bib42","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/nature07976","article-title":"Autophagy regulates lipid metabolism","volume":"458","author":"Singh","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.cmet.2014.05.001_bib43","doi-asserted-by":"crossref","first-page":"721","DOI":"10.7164\/antibiotics.28.721","article-title":"Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle","volume":"28","author":"V\u00e9zina","year":"1975","journal-title":"J.\u00a0Antibiot."},{"issue":"Suppl 2","key":"10.1016\/j.cmet.2014.05.001_bib44","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1002\/lt.23515","article-title":"Reducing the load: the evolution and management of obesity and nonalcoholic steatohepatitis before liver transplantation","volume":"18","author":"Watt","year":"2012","journal-title":"Liver Transpl."},{"key":"10.1016\/j.cmet.2014.05.001_bib45","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.immuni.2008.08.012","article-title":"The TSC-mTOR signaling pathway regulates the innate inflammatory response","volume":"29","author":"Weichhart","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.cmet.2014.05.001_bib46","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.cell.2006.01.016","article-title":"TOR signaling in growth and metabolism","volume":"124","author":"Wullschleger","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.cmet.2014.05.001_bib47","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/cam4.150","article-title":"Therapeutic potential and adverse events of everolimus for treatment of\u00a0hepatocellular carcinoma - systematic review and meta-analysis","volume":"2","author":"Yamanaka","year":"2013","journal-title":"Cancer Med"},{"key":"10.1016\/j.cmet.2014.05.001_bib48","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.4161\/cc.10.22.18124","article-title":"High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1","volume":"10","author":"Yellen","year":"2011","journal-title":"Cell Cycle"},{"key":"10.1016\/j.cmet.2014.05.001_bib49","doi-asserted-by":"crossref","first-page":"5094","DOI":"10.1002\/cncr.26165","article-title":"Phase 1\/2 study of everolimus in advanced hepatocellular carcinoma","volume":"117","author":"Zhu","year":"2011","journal-title":"Cancer"}],"container-title":["Cell Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1550413114002095?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1550413114002095?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,11]],"date-time":"2019-08-11T08:49:46Z","timestamp":1565513386000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1550413114002095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S1550413114002095"],"URL":"https:\/\/doi.org\/10.1016\/j.cmet.2014.05.001","relation":{},"ISSN":["1550-4131"],"issn-type":[{"value":"1550-4131","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Liver Damage, Inflammation, and Enhanced Tumorigenesis after Persistent mTORC1 Inhibition","name":"articletitle","label":"Article Title"},{"value":"Cell Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmet.2014.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}